This article is more than 5 years old. Information may no longer be current.
FDA grants orphan drug designation to Triolimus for angiosarcoma
Click Here to Manage Email Alerts
The FDA granted orphan drug designation to Triolimus for the treatment of patients with angiosarcoma, according to a press release from the drug’s manufacturer.
Triolimus (Co-D Therapeutics) is a combination of three complementary anti-cancer agents — paclitaxel, rapamycin and tanespimycin (17-AAG) — in a non-toxic carrier.
Glen S. Kwon, PhD, co-founder and chief scientific officer of Co-D Therapeutics and professor at the University of Wisconsin-Madison, developed Triolimus.
"We are excited to continue the enormously rewarding process of advancing Triolimus to the clinic," Kwon said in a press release.
"We are pleased that Triolimus has been designated an orphan drug for the treatment of angiosarcoma," Kevin Kozak, MD, co-founder and chief medical officer of Co-D Therapeutics, said in a press release. "With few effective options, new agents for angiosarcoma treatment are urgently required. The orphan designation reflects both the FDA's and Co-D's commitment to addressing the unmet clinical needs of patients with rare diseases like angiosarcoma.”
The FDA’s Office of Orphan Products Development grants orphan drug designation to novel drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States.